Board of Directors

William Ashton is a former Fortune 100 senior executive with over 40 years’ experience in the biotechnology and pharmaceutical business. Mr. Ashton has retired from an extensive career at Amgen Inc. While with Amgen he served in various positions including Vice President of U.S. Sales for Amgen. He also served as Vice President/General Manager of the Corporate Accounts, Business Unit. This unit has responsibility for the sales and marketing to Amgen's largest customer base including health systems, managed care organizations, commercial and government payers, distribution channels, GPO’s and the corporate pricing group.

Since the beginning of 2013, Mr. Ashton has been a principal at Harrison Consulting Group, LLC, a privately held biopharmaceutical consulting firm with expertise in commercialization, payer strategy, and reimbursement.

Mr. Ashton currently serves on the board of a publicly traded company, Recro Pharma. He previously served on the boards of Sucampo Pharmaceuticals and Galena Bio Pharma. In addition, he has served on the boards of the National Osteoporosis Foundation, Friends of the National Library of Medicine, and is a Commissioner on the Medical Representatives National Certification Commission.

Brittany K. Bradrick is currently the Chief Financial Officer at Neurelis, Inc., a commercial stage neuroscience company. She has 25 years of experience in finance, strategy, and corporate development for life science companies, with both operational and advisory experience. Prior to joining Neurelis, Ms. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte. She previously served in strategy and corporate development positions for 10 years at Insulet Corporation as Vice President, Strategy & Corporate Development and at Abbott Diabetes Care as the Head of Global Business Development. Prior to these positions, Ms. Bradrick was an investment banker for the life sciences sector at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years. Ms. Bradrick began her career as a Federal Reserve Bank Examiner.

Ms. Bradrick holds an MBA from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.

Juhyun Lim joined Spectrum’s Board of Directors in January 2022. She is an experienced life sciences executive and currently serves as President, Global Strategy and Planning at Hanmi Science and Hanmi Pharmaceutical, where she leads the execution of corporate strategy and investment.

She also serves as Director, Healthcare Investment at Hanmi Venture. Ms. Lim has held various senior leadership roles during her tenure at Hanmi, including SVP, Human Resource Development.

Ms. Lim received a Master of Arts from Boston University and a Bachelor of Arts from Smith College.

Thomas Riga is Spectrum’s President and Chief Executive Officer. Mr. Riga was named Spectrum’s President and Chief Executive Officer on January 1st, 2022. He has over 20 years of diverse pharmaceutical leadership experience. He has leadership experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. and Dendreon Pharmaceuticals LLC. Throughout his career he has successfully integrated leadership and strategy to create meaningful value. His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma, manufacturing, and corporate accounts.

During his tenure at Spectrum, Mr. Riga has led a strategic shift in the company’s focus from a specialty pharmaceutical company to a development-focused organization. The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets. Additionally, he has led multiple product launches in the oncology market, delivering innovative cancer care while establishing world class partnerships with key industry stakeholders. He has consistently inspired cross-functional teams to deliver superior performance to create value for Spectrum.

Mr. Riga holds a bachelor’s degree in Biology and Chemistry from St. Lawrence University, Canton, New York. Mr. Riga is an accredited public company director from UCLA’s Anderson School of Business.

Jeffrey Vacirca, MD, FACP is a board certified hematologist and oncologist at New York Cancer & Blood Specialists, where he serves as CEO and managing partner. His specialties include breast cancer, prostate cancer, and complicated cancers.

Currently, Dr. Vacirca is the president of the Community Oncology Alliance (COA), medical director for Amerisource Bergen specialty group, a Scientific Advisory Board Member for Caris Life Sciences, president and co-founder of National Translational Research Group, and serves as a medical board advisor for Flatiron Health.

Additionally, he is the vice-chairmen of the board for Odonate Therapeutics, a company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Furthermore, he has joined the Board of Directors for One Oncology, an oncologist-led company providing oncologists with innovative tools to help keep cancer care in the hands of the providers.

Dr. Vacirca received his undergraduate degree from the University at Albany and his medical degree from St. George’s University School of Medicine. He completed his residency in internal medicine along with his fellowships in hematology and medical oncology at Stony Brook University Hospital. In his final year of training, he was named chief fellow.

Dr. Vyas has 31 years tenure in oncology drug discovery research at Bristol-Myers Squibb Company (\"BMS\"), a NYSE-listed pharmaceutical company, most recently as a Group Director and Distinguished Research Fellow. In 1980, he joined BMS in the Antitumor Chemistry department and was involved in National Cancer Institute/National Institute of Health funded collaborative research efforts on discovery of novelv natural product based cytotoxics to treat human neoplasms (tumors).

In 1984, he was promoted to Research Fellow and in subsequent years he held positions as an Associate Director, Director and Group Director, which culminated in 1999 in his last promotion at BMS as a Distinguished Research Fellow (Executive Level) in Oncology Discovery Chemistry at the Wallingford, Connecticut site. Dr. Vyas is considered one of the pioneers of the BMS oncology medicinal chemistry discovery efforts based on natural products derived cytotoxics. During this period he was also involved in BMS's pioneering research on antibody drug conjugate (\"ADC\") technology to target cytotoxics selectively to tumors. This technology in recent years has yielded valuable new biologics for treating a variety of cancers.

In the last 15 years of his oncology research career at BMS, he was involved in discovery and development of personalized medicine research involving small molecule molecular targeted oncology therapeutics (e.g. kinase inhibitors). During his tenure at BMS in oncology drug discovery, he has participated in the discovery and development of 12 small molecules and one biologic (ADC) as clinical development candidates with one US Food and Drug Administration approved NDA.

He has authored/co-authored over 110 publications and written numerous book chapters and review articles. He is also an inventor/co-inventor on more than 40 patents. He has been a plenary and invited speaker at conferences and at academic institutions in the US and abroad. In 1994 he was a co-organizer of American Chemical Society (ACS) Medicinal Chemistry Symposium on \"Advances in Medicinal Chemistry of Taxol and Taxoids\" at the 207th ACS National Meeting in San Diego, California. He is an elected member of the Connecticut Academy of Sciences and Engineering (\"CASE\") and is also on the editorial board of Medicinal Research Reviews. He has participated in National Institute of Health and CASE study sections to review small business industry research proposals and biomedical research proposals for funding in Connecticut, respectively.

Dr. Vyas retired from BMS in 2011 and has subsequetly formed a research and development consulting company, Dinesh Vyas, LLC. Currently, he is consulting for two India-based pharmaceutical companies.

Dr. Vyas received a B.Sc. with honors degree in Chemistry/Geology from University College Nairobi (Kenya), University of East Africa in 1967 and a Ph.D. degree in Organic Chemistry from Queens University, Kingston, Canada in 1972.

Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC. Previously, Mr. Fischer served as the Chief Executive Officer and as a Director of Vivus, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health from September 2013 to December 2017.

Prior to Vivus, Mr. Fischer served in various positions of increasing responsibility at Johnson & Johnson, most recently as company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Prior to that, he served as company Group Chairman, North America Pharmaceuticals, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals. Mr. Fischer’s operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including neurologic products for epilepsy and migraines and products in the analgesic, anti-infective, cardiovascular, psychiatric and women’s health areas. From May 2013 to May 2019, Mr. Fischer also served on the Board of Directors of BioSig Technologies, Inc.

Mr. Fischer brings to the Board over 37 years of experience in the pharmaceutical industry, including 29 years in various leadership roles at Johnson & Johnson.